RELAY THERAPEUTICS INC (RLAY) Forecast, Price Target & Analyst Ratings
NASDAQ:RLAY • US75943R1023
9.89 USD
+0.25 (+2.59%)
At close: Mar 6, 2026
9.9 USD
+0.01 (+0.1%)
After Hours: 3/6/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RELAY THERAPEUTICS INC (RLAY).
Forecast Snapshot
Consensus Price Target
$14.84
+ 50.01% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.38
Revenue Estimate102K
ChartMill Buy Consensus
87.78%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$14.84
Upside
+ 50.01%
From current price of $9.89 to mean target of $14.84, Based on 18 analyst forecasts
Low
$12.12
Median
$14.28
High
$19.95
Price Target Revisions
1 Month
-0.37%
3 Months
4.64%
Price Target Summary
18 analysts have analysed RLAY and the average price target is 14.84 USD. This implies a price increase of 50.01% is expected in the next year compared to the current price of 9.89.
The average price target has been revised upward by 4.64% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.78%
RLAY was analyzed by 18 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about RLAY.
In the previous month the buy percentage consensus was at a similar level.
RLAY was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-27 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-26 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-12-12 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2025-11-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-08 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-05-07 | Guggenheim | Maintains | Buy -> Buy |
| 2025-04-17 | Wells Fargo | Initiate | Equal-Weight |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-27 | Stifel | Maintains | Buy -> Buy |
| 2025-02-27 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-12-04 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-12-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-17 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-16 | Stifel | Reiterate | Buy -> Buy |
| 2024-09-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-10 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2024-09-10 | Barclays | Maintains | Overweight -> Overweight |
| 2024-09-10 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-09-10 | Goldman Sachs | Reiterate | Buy |
| 2024-09-10 | B of A Securities | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.38
Revenue Estimate102K
Revenue Q2Q-98.67%
EPS Q2Q16.38%
Number of Analysts13
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
-0.22%
EPS (3 Months)
1.75%
Next Earnings Summary
RLAY is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.38 USD and the consensus revenue estimate is 102.00K USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 25.546M 1,751.16% | 10.007M -60.83% | 15.355M 53.44% | 4.103M -73.28% | 20.351M 396.00% | 8.907M -56.23% | 89.325M 902.86% | 299.51M 235.30% | 591.13M 97.37% | 1.017B 72.04% | 873.04M -14.16% | |
| EBITDA YoY % growth | -367.731M -24.59% | -367.004M 0.20% | -299.181M 18.48% | -292.342M 2.29% | -271.902M 6.99% | -340.848M -25.36% | -89.689M 73.69% | 123.87M 238.11% | 245.7M 98.35% | 367.12M 49.42% | 430.12M 17.16% | |
| EBIT YoY % growth | -373M -24.63% | -372.468M 0.14% | -302.738M 18.72% | -323.53M -6.87% | -327.457M -1.21% | -347.888M -6.24% | -271.77M 21.88% | -132M 51.43% | 126.94M 196.17% | 446.13M 251.45% | 441.58M -1.02% | |
| Operating Margin | -1,460.11% | -3,722.07% | -1,971.59% | -7,885.20% | -1,609.04% | -3,905.79% | -304.25% | -44.07% | 21.47% | 43.87% | 50.58% | |
| EPS YoY % growth | -2.80 -7.69% | -2.39 14.64% | -1.62 32.22% | -1.63 -0.47% | -1.56 4.30% | -1.56 -0.02% | -0.68 56.14% | 0.03 104.48% | 0.98 3,116.67% | 2.69 173.58% | 1.96 -27.27% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.38 16.38% | -0.40 1.64% | -0.43 0.88% | -0.38 -17.83% | -0.35 9.84% | -0.35 14.00% | -0.35 18.63% | -0.28 26.96% |
| Revenue Q2Q % growth | 102K -98.67% | 102K -84.93% | 5.1M -27.14% | -100.00% | -100.00% | 15.616M 206.20% | ||
| EBITDA Q2Q % growth | -74.428M 11.04% | -72.338M 3.08% | -73.812M 4.68% | -48.878M 14.36% | -65.576M 11.89% | -66.3M 8.35% | -68.34M 7.41% | -53.04M -8.51% |
| EBIT Q2Q % growth | -70.968M 16.38% | -75.354M 1.94% | -81.333M -1.17% | -77.198M -27.33% | -66.473M 6.33% | -67.463M 10.47% | -68.493M 15.79% | -53.917M 30.16% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
1.26%
EPS Next 5 Year
15.09%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-9.47%
Revenue Next 5 Year
90.29%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-1.56%
EBIT Next 5 Year
18.94%
RELAY THERAPEUTICS INC / RLAY Forecast FAQ
What do analysts expect the price target to be for RELAY THERAPEUTICS INC (RLAY)?
18 analysts have analysed RLAY and the average price target is 14.84 USD. This implies a price increase of 50.01% is expected in the next year compared to the current price of 9.89.
What is the next earnings date for RLAY stock?
RELAY THERAPEUTICS INC (RLAY) will report earnings on 2026-05-04.
What are the consensus estimates for RLAY stock next earnings?
The consensus EPS estimate for the next earnings of RELAY THERAPEUTICS INC (RLAY) is -0.38 USD and the consensus revenue estimate is 102.00K USD.
Can you provide the expected long term growth rate for RELAY THERAPEUTICS INC stock?
The expected long term growth rate for RELAY THERAPEUTICS INC (RLAY) is -9.47%.